Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

Pfizer just penned a $6 billion licensing deal with China's 3SBio to develop and commercialize a cancer drug, SSGJ-707. The ...

Seongnam: SK bioscience, a global vaccine and biotech company, has announced that the Supreme Court of Korea has ruled in its ...

The pharma giant entered an exclusive agreement with the Chinese biotech to gain rights to a cancer bispecific drug candidate.

The company bought the rights to an experimental cancer drug for $1.3 billion, plus potential milestone payments of $4.8 ...

Bernstein analysts reaffirmed their Market Perform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on May 20, ...

3SBio, along with its subsidiaries Shenyang Sunshine Pharmaceutical and 3S Guojian Pharmaceutical (Shanghai), will grant Pfizer exclusive global rights to SSGJ-707 outside of China. Pfizer retains the ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

To increase women representation in the pharmaceutical industry, Pfizer Global Supply’s manufacturing unit in Visakhapatnam ...

Pfizer and GITAM University empower rural women with employment through Pfizer autonomous teams programme: Our Bureau, Bengaluru Friday, May 23, 2025, 13:30 Hrs [IST] Pfizer Globa ...